Apriori Bio develops a platform for creating variant-resilient vaccines using real-time data analytics to enhance preparedness for viral outbreaks. This technology enables rapid adaptation to emerging viral threats, ensuring effective immunization strategies in response to evolving pathogens.
Funding
$51.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CFFounders
Product
Problem
Viral outbreaks pose a significant threat to global health, and traditional vaccine development processes are often too slow to respond effectively to emerging variants. This lag time can result in widespread illness and mortality before effective immunization strategies can be deployed.
Solution
Apriori Bio has developed a technology platform that leverages real-time data analytics to design variant-resilient vaccines, enhancing preparedness for future viral outbreaks. By continuously monitoring viral evolution and identifying conserved epitopes, the platform enables rapid adaptation of vaccine candidates to address emerging threats. This approach aims to create vaccines that offer broad protection against existing and future viral variants, ensuring more effective immunization strategies. The platform's ability to learn from current viral activity allows for proactive development of countermeasures, reducing the impact of future pandemics.
Target Audience
The primary target audience includes global health organizations, government agencies, and pharmaceutical companies focused on developing and deploying effective vaccines against viral threats.
Features
- Real-time data analytics for continuous monitoring of viral evolution
- Identification of conserved epitopes to target in vaccine design
- Rapid adaptation of vaccine candidates to address emerging variants
- Prediction of future viral mutations to proactively develop countermeasures
- Development of variant-resilient vaccines for broad protection